Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the recurrence score® in node-positive breast cancer: Independent validation in the PACS-01 trial
European Journal of Cancer · 2026
DOI: 10.1016/j.ejca.2025.116152 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Frédérique Penault-Llorca und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biopathology, Centre Jean Perrin, Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, Clermo…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Hormonal, Breast Neoplasms, Neoplasm Recurrence, Local. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Prevention and Research Institute of Texas, Breast Cancer Research Foundation, Amgen.
Abstract (Originalsprache)
Aim
To independently confirm whether the combination of sensitivity to endocrine therapy (SET2,3) index and Recurrence Score® (RS) improves prognostic assessment for patients with hormone receptor-positive (HR+) lymph node-positive (LN+) breast cancer. Secondly, to evaluate SET ER/PR index, the component of SET2,3 that measures endocrine transcriptional activity.
Methods
HR+ tumor samples from the PACS-01 trial were tested for RS and SET2,3 index. Pre-defined cut points defined high-risk if RS >25 or SET2,3
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biopathology, Centre Jean Perrin, Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, Clermont Ferrand F-63000, France. Electronic address: frederique.penault-llo…
- Department of Biostatistics, Oncopole Claudius Regaud, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France.
- Departments of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Exact Sciences, Madison, WI, USA; Department of Pathology, University of California, San Francisco, CA, USA.
- Department of Medical Oncology, Oncopole Claudius Regaud, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France.
- Department of Pathology, Institut Gustave Roussy, Villejuif, France.
Förderung
- Cancer Prevention and Research Institute of Texas
- Breast Cancer Research Foundation
- Amgen
- National League Against Cancer
- Sanofi France
Zitieren
APA
Penault-Llorca, F., Lusque, A., Filleron, T., Tran, K., Du, L., Baehner, R., Dalenc, F., Lacroix-Triki, M., Bachelot, T., Andre, F., Boucher, P., Lemonnier, J., & Fraser Symmans, W. (2026). Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the recurrence score® in node-positive breast cancer: Independent validation in the PACS-01 trial. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.116152
Vancouver
Penault-Llorca F, Lusque A, Filleron T, Tran K, Du L, Baehner R, et al. Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the recurrence score® in node-positive breast cancer: Independent validation in the PACS-01 trial. European Journal of Cancer. 2026. doi:10.1016/j.ejca.2025.116152
BibTeX
@article{PenaultLlorca2026,
author = {Penault-Llorca, Frédérique and Lusque, Amelie and Filleron, Thomas and Tran, Kevin and Du, Lili and Baehner, Rick and Dalenc, Florence and Lacroix-Triki, Magali and Bachelot, Thomas and Andre, Fabrice and Boucher, Pascal and Lemonnier, Jérôme and Fraser Symmans, W},
title = {Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the recurrence score® in node-positive breast cancer: Independent validation in the PACS-01 trial},
journal = {European Journal of Cancer},
year = {2026},
doi = {10.1016/j.ejca.2025.116152}
}
EUVIMED